Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSP-2020 PET Receptor Occupancy and PK Study in Healthy Male Adults
NCT07329621Phase 1Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MSP-2020 in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Percent Change in Specific Binding of [11C]CIMBI-36 from Baseline at Day 2, PK Plasma Concentration of MSP-2020 and its Metabolite at Day 2 and 4 more. Started Jan 2026; status: terminated.
02
Drugs
MSP-2020
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07329621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07329621.